Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dtxsid10151274
Molecular Weight | 5832 g/mol |
---|---|
Molecular Formula | C256H387N65O79S6 |
Hydrogen Bond Donor Count | 86 |
Hydrogen Bond Acceptor Count | 91 |
Rotatable Bond Count | 188 |
Exact Mass | 5829.6654893 g/mol |
Monoisotopic Mass | 5827.6587796 g/mol |
Topological Polar Surface Area | 2350 Ų |
Heavy Atom Count | 406 |
Formal Charge | 0 |
Complexity | 13000 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 52 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Novolog |
PubMed Health | Insulin Aspart Protamine/Insulin Aspart (Injection) |
Drug Classes | Antidiabetic |
Drug Label | NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b... |
Active Ingredient | Insulin aspart recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Novo Nordisk |
2 of 2 | |
---|---|
Drug Name | Novolog |
PubMed Health | Insulin Aspart Protamine/Insulin Aspart (Injection) |
Drug Classes | Antidiabetic |
Drug Label | NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b... |
Active Ingredient | Insulin aspart recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Novo Nordisk |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
23
PharmaCompass offers a list of Insulin aspart API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Insulin aspart manufacturer or Insulin aspart supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Insulin aspart manufacturer or Insulin aspart supplier.
PharmaCompass also assists you with knowing the Insulin aspart API Price utilized in the formulation of products. Insulin aspart API Price is not always fixed or binding as the Insulin aspart Price is obtained through a variety of data sources. The Insulin aspart Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A RYZODEG 70/30 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RYZODEG 70/30, including repackagers and relabelers. The FDA regulates RYZODEG 70/30 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RYZODEG 70/30 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A RYZODEG 70/30 supplier is an individual or a company that provides RYZODEG 70/30 active pharmaceutical ingredient (API) or RYZODEG 70/30 finished formulations upon request. The RYZODEG 70/30 suppliers may include RYZODEG 70/30 API manufacturers, exporters, distributors and traders.
click here to find a list of RYZODEG 70/30 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A RYZODEG 70/30 DMF (Drug Master File) is a document detailing the whole manufacturing process of RYZODEG 70/30 active pharmaceutical ingredient (API) in detail. Different forms of RYZODEG 70/30 DMFs exist exist since differing nations have different regulations, such as RYZODEG 70/30 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A RYZODEG 70/30 DMF submitted to regulatory agencies in the US is known as a USDMF. RYZODEG 70/30 USDMF includes data on RYZODEG 70/30's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The RYZODEG 70/30 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of RYZODEG 70/30 suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing RYZODEG 70/30 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for RYZODEG 70/30 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture RYZODEG 70/30 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain RYZODEG 70/30 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a RYZODEG 70/30 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of RYZODEG 70/30 suppliers with NDC on PharmaCompass.
RYZODEG 70/30 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RYZODEG 70/30 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RYZODEG 70/30 GMP manufacturer or RYZODEG 70/30 GMP API supplier for your needs.
A RYZODEG 70/30 CoA (Certificate of Analysis) is a formal document that attests to RYZODEG 70/30's compliance with RYZODEG 70/30 specifications and serves as a tool for batch-level quality control.
RYZODEG 70/30 CoA mostly includes findings from lab analyses of a specific batch. For each RYZODEG 70/30 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RYZODEG 70/30 may be tested according to a variety of international standards, such as European Pharmacopoeia (RYZODEG 70/30 EP), RYZODEG 70/30 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RYZODEG 70/30 USP).